SCHEMBL4348239

SCHEMBL4348239

O=C(O)Nc1cccc(NS(=O)(=O)c2cccc(Nc3nc(Cl)ncc3Cl)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 4/20 0.54
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.45
MEN1 O00255 2/20 0.45
HTT P42858 2/20 0.45
KMT2A Q03164 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
EGFR P00533 2/20 0.44
PKM P14618 1/20 0.44
MAPK1 P28482 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
STAT3 P40763 1/20 0.44
JAK1 P23458 2/20 0.44
HDAC1 Q13547 2/20 0.44
IDH1 O75874 2/20 0.43
MET P08581 1/20 0.43
ALK Q9UM73 1/20 0.43
PCTP Q9UKL6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13623014 0.86 BTK (0.49) BTKLMNAMAPTMEN1HTT
SCHEMBL1025031 0.85 POLB (0.53) BTKMEN1KMT2APKMJAK1
SCHEMBL1025665 0.83 JAK1 (0.45) BTKLMNAMAPTMEN1HTT
SCHEMBL4334678 0.83 MET (0.47) BTKKMT2AEGFRALDH1A1MET
SCHEMBL1026707 0.81 MEN1 (0.49) MEN1KMT2AEGFR
SCHEMBL1025877 0.80 ALDH1A1 (0.53) LMNAMAPTMEN1HTTKMT2A
SCHEMBL18757767 0.79 BRD4 (0.59) BTKMAPTHTTEGFRPKM
SCHEMBL4334439 0.78 KMT2A (0.46) BTKLMNAMAPTMEN1KMT2A
SCHEMBL1082504 0.78 JAK3 (0.48) BTKEGFRJAK1
SCHEMBL28782963 0.77 CTSL (0.57) MAPTMEN1KMT2AEGFRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK BTK 20/4885LMNA 4393/4885MAPT 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.